Remuneration committee charter
Board of Directors
Cochlear aims to have a Board of an effective composition, size and commitment to adequately discharge its responsibilities and duties.
The Board of Directors currently comprises six independent Non-Executive Directors, including the Chairperson and one Executive Director, the Chief Executive Officer/President.
A majority of the Board must be independent Non-Executive Directors.
The Chairperson must be an independent Non-Executive Director.
The roles of the Chairperson and Chief Executive Officer/President must not be exercised by
An independent director is a Non-Executive Director who is not a member of management and who is free of any business or other relationship that could materially interfere with the independent exercise of their judgement.
Responsibilities of the Board
Oversight of the Company, including its control and accountability systems.
Appointing and removing the Chief Executive Officer/President.
Ratifying the appointment and, where appropriate, the removal of the CFO and the Company
Input into a final approval of management’s development of corporate strategy and
Reviewing and ratifying systems of risk management and internal compliance and control,
Monitoring senior management’s performance and implementation of strategy and ensuring
Approving and monitoring the progress of major capital expenditure, capital management and
acquisitions and divestitures and dividend policy.
Approving and monitoring financial and other reporting.
Relationship with Chief Executive Officer/President
The Board has delegated responsibility for day-to-day management of Cochlear to the Chief Executive Officer/President. However, the Chief Executive Officer/President must consult the Chairperson on matters that are sensitive, extraordinary or of a strategic nature.
The Board operates through Committees that are responsible for particular areas of the business. The five existing Committees are the Audit Committee, the Remuneration Committee, the Technology and Innovation Committee, the Medical Science Committee and the Nomination Committee. Each Committee operates in accordance with a written charter or terms of reference.
These Committees enable a more detailed involvement of the Board with the business in line with the Committee Charter or terms of reference.
Internal Policies Applicable to Directors
Cochlear has in place the following internal operating policies, which apply personally to Directors:
Non-Executive Directors and Executives Share Ownership Policy
The Board is also ultimately responsible for ensuring compliance of Cochlear officers and employees with other Company policies including:
CURRENT BOARD MEMBERSHIP
Mrs Yasmin Allen Mr Paul Bell Prof Edward Byrne Mr Andrew Denver Mr Roderic Holliday-Smith Mr Donal O’Dwyer
Pisa – Ippodromo di San Rossore – Partenti di domenica 06 gennaio 2013 Ore 13.40 - PREMIO TONINO CIUCCI (PIANA)(CONDIZIONATA)(G.R.-AM.) E 6.000,00 ( E 2.600,40 - 1.144,20 - 624,00 - 312,00 e E 390,00 - 150,00 - 60,00 agli allevatori), per cavalli di 4 anni ed oltre che non abbiano vinto la somma di E 12.000 dal 06/08/2012 o un premio di E 3.825 dal 06/08/2012 o due corse dal
T. M. Glaus, G. Wess, Band 152, Heft 3, März 2010, xxx – xxx © 2010 by Verlag Hans Huber, Hogrefe AG, Bern Originalarbeiten 1 Linksherzhypertrophie bei der Katze – „wenn eine hypertrophe Kardiomyopathie keine hypertrophe Kardiomyopathie ist“ T. M. Glaus1, G. Wess2 1Abteilung für Kardiologie, Klinik für Kleintiermedizin, Universität Zürich, 2Abteilung für Kardiologie,